Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Iglesias

Vascular & Interventional Radiology Miami, FL Medical Doctor

NPI 1235517558 CMS profile 1329550

1321 Nw 14Th St, Miami, FL 33125

Open in the dashboard

General payments

$19,258

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Iglesias of Miami, FL is reported in the CMS Open Payments database as having received $19,258 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,237 30
2024 General $1,191 27
2023 General $5,134 51
2022 General $5,600 41
2021 General $2,206 14
2019 General $1,889 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Iglesias
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Jonathan Iglesias were reported at $3,237. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Jonathan Iglesias Vascular & Interventional Radiology median Middle half National median
2019 $1,889 $422 $125–$1,555 $163
2020 $0 $200 $68–$652 $114
2021 $2,206 $280 $99–$866 $132
2022 $5,600 $433 $137–$1,497 $149
2023 $5,134 $506 $152–$2,019 $160
2024 $1,191 $556 $175–$1,930 $164
2025 $3,237 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $8,052 46 payments
  2. Philips Electronics North America Corporation $2,784 27 payments
  3. Terumo Medical Corporation $2,101 27 payments
  4. AngioDynamics, Inc. $1,994 3 payments
  5. Medtronic, Inc. $1,678 14 payments
  6. Cook Medical LLC $770 15 payments
  7. Shockwave Medical, Inc $709 11 payments
  8. Inari Medical, Inc. $651 7 payments
  9. Abbott Laboratories $162 5 payments
  10. Bard Peripheral Vascular, Inc. $134 1 payment
  11. Other $223 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,250 149 payments
  2. Travel and Lodging $5,808 16 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,200 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $6,118 32 payments
  2. GLIDEWIRE $1,662 11 payments
  3. KYPHON EXPRESS II KYPHOPAK TRAY $1,123 9 payments
  4. Penumbra Coil 400 $866 2 payments
  5. CT THROMBECTOMY SYSTEM KIT $651 7 payments
  6. FLOWTRIEVER CATHETER, S $651 7 payments
  7. Penumbra System $590 8 payments
  8. RUBY Coil $477 4 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $414 7 payments
  10. (AZ7) Lasers $392 4 payments
  11. Other $5,800 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

83

Median for Interventional Radiology: 38

Drug cost

$42,615

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 39 $32,410
Eliquis Apixaban Brand 13 $9,708
Clopidogrel Clopidogrel Bisulfate Brand 31 $496

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$185,202

Medicare's payments for the services billed

Medicare patients

175

Average age 76

Services billed

589

82 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 54%
Ischemic heart disease 49%
Chronic kidney disease 44%
Atrial fibrillation 27%
Depression 27%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record